BR9812357A - Tratamento de distúbio oposicional desafiador - Google Patents

Tratamento de distúbio oposicional desafiador

Info

Publication number
BR9812357A
BR9812357A BR9812357-2A BR9812357A BR9812357A BR 9812357 A BR9812357 A BR 9812357A BR 9812357 A BR9812357 A BR 9812357A BR 9812357 A BR9812357 A BR 9812357A
Authority
BR
Brazil
Prior art keywords
challenging
disorder treatment
oppositional
oppositional disorder
treatment
Prior art date
Application number
BR9812357-2A
Other languages
English (en)
Inventor
John Harrison Heiligenstein
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BR9812357A publication Critical patent/BR9812357A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Patente de Invenção:<B>"TRATAMENTO DE DISTúRBIO OPOSICIONAL DESAFIADOR"<D>. Inibidores de reabsorção de norepinefrina são utilizados para tratar distúrbio oposicional desafiador.
BR9812357-2A 1997-09-23 1998-09-01 Tratamento de distúbio oposicional desafiador BR9812357A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5962997P 1997-09-23 1997-09-23
PCT/US1998/018114 WO1999015176A1 (en) 1997-09-23 1998-09-01 Treatment of oppositional defiant disorder

Publications (1)

Publication Number Publication Date
BR9812357A true BR9812357A (pt) 2000-09-12

Family

ID=22024203

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9812357-2A BR9812357A (pt) 1997-09-23 1998-09-01 Tratamento de distúbio oposicional desafiador

Country Status (17)

Country Link
US (1) US6028070A (pt)
EP (1) EP0919236A1 (pt)
JP (1) JP2001517627A (pt)
KR (1) KR20010024218A (pt)
CN (1) CN1146412C (pt)
AU (1) AU740109B2 (pt)
BR (1) BR9812357A (pt)
CA (1) CA2304115A1 (pt)
EA (1) EA002689B1 (pt)
HU (1) HUP0003591A3 (pt)
IL (1) IL134716A0 (pt)
NO (1) NO20001458L (pt)
NZ (1) NZ502810A (pt)
PL (1) PL339426A1 (pt)
TR (1) TR200000755T2 (pt)
UA (1) UA56257C2 (pt)
WO (1) WO1999015176A1 (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999052531A1 (en) 1998-04-09 1999-10-21 Pharmacia & Upjohn Company New treatments for nervous disorders
US6500827B2 (en) * 1998-05-08 2002-12-31 Pharmacia & Upjohn Company Drug combinations
EP1500395B1 (en) * 1999-07-01 2006-03-08 Pharmacia & Upjohn Company LLC Reboxetine for treating fibromyalgia and other somatoform disorders
PT1632234E (pt) * 1999-07-01 2007-07-09 Pharmacia & Upjohn Co Llc (s,s)-reboxetina para o tratamento da síndrome de fadiga crónica
CO5210862A1 (es) * 1999-09-15 2002-10-30 Alza Corp Formas de dosificacion y metodos para proporcionar efectiva terapia de reboxetina con dosificacion de una vez al dia
CN1407890A (zh) * 2000-03-07 2003-04-02 伊莱利利公司 牛皮癣的治疗
EP1383465B1 (en) * 2001-03-29 2011-08-10 Michael Davis Acute pharmacologic augmentation of psychotherapy with d-cycloserine
US6613763B2 (en) 2001-04-20 2003-09-02 Mgi Applied Genomics Use of molindone to treat oppositional defiant disorder and conduct disorder
US6602911B2 (en) * 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
IL146462A (en) * 2001-11-13 2015-02-26 Lycored Bio Ltd Prolonged-release preparations containing as an active compound and analapaxin hydrochloride
WO2003068211A1 (en) * 2002-02-12 2003-08-21 Cypress Bioscience, Inc. Methods of treating attention deficit/hyperactivity disorder (adhd)
AU2003225837B2 (en) * 2002-03-15 2008-11-06 Forest Laboratories Holdings Limited NE and 5-HT reuptake inhibitors for treating visceral pain syndromes
CA2481934A1 (en) * 2002-04-18 2003-10-30 Pharmacia Corporation Combinations of cox-2 inhibitors and other agents for the treatment of parkinson's disease
EP1499309A4 (en) * 2002-04-24 2008-05-28 Cypress Bioscience Inc PREVENTION AND TREATMENT OF FUNCTIONAL SOMATIC DISEASES, INCLUDING STRESS-BASED DISEASES
AU2003243172A1 (en) * 2002-04-29 2003-11-17 Alza Corporation Reduced formate poly(alkylene oxides) with secondary amines for reducing impurity formation
BR0311878A (pt) * 2002-06-17 2005-04-05 Pharmacia Italia Spa Sais farmacêuticos de reboxetina
US20040204411A1 (en) * 2002-12-17 2004-10-14 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
US20040235925A1 (en) * 2002-12-17 2004-11-25 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of duloxetine, venlafaxine or atomoxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
PT1601349E (pt) * 2003-02-14 2008-10-27 Pf Medicament Utilização do enantiómero (1s, 2r) do milnaciprano para a preparação de um medicamento
FR2851163B1 (fr) * 2003-02-14 2007-04-27 Utilisation de l'enantiomere dextrogyre du milnacipran pour la preparation d'un medicament
GB0309440D0 (en) * 2003-04-25 2003-06-04 Lilly Co Eli Quinolone derivatives
US20060100290A1 (en) * 2003-07-28 2006-05-11 Dunaway Leslie J Treatment of allergic rhinitis and asthma
CA2552064A1 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Atomoxetine formulations
US20060084659A1 (en) * 2004-10-19 2006-04-20 Michael Davis Augmentation of psychotherapy with cannabinoid reuptake inhibitors
US7994220B2 (en) * 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
US20080081067A1 (en) * 2006-10-03 2008-04-03 Gupta Manishkumar Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof
US20100069389A1 (en) * 2008-09-06 2010-03-18 Bionevia Pharmaceuticals, Inc. Novel forms of reboxetine
CA2779711C (en) * 2009-11-06 2016-11-01 Forest Laboratories Holding Limited Novel crystalline forms of (1s,2r)-2-(amino methyl)-n,n-diethyl-1-phenyl cyclopropane carboxamide
PT2931291T (pt) 2012-12-11 2021-12-03 Mclean Hospital Corp Tratamento com xénon como complemento da psicoterapia para perturbações psiquiátricas

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL56369A (en) * 1978-01-20 1984-05-31 Erba Farmitalia Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them
EP0537915B1 (en) * 1991-09-27 1995-07-12 Eli Lilly And Company N-alkyl-3-phenyl-3-(2-alkylthiophenoxy)propylamines as norepinephrine inhibitors
ZA93694B (en) * 1993-02-01 1993-06-03 Lilly Co Eli Pharmaceutical treatments.
CA2134038C (en) * 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
ZA958725B (en) * 1994-10-20 1997-04-16 Lilly Co Eli Treatment of disorders with duloxetine
US5658590A (en) * 1995-01-11 1997-08-19 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
US5696168A (en) * 1995-07-24 1997-12-09 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
AU709704B2 (en) * 1995-07-24 1999-09-02 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder

Also Published As

Publication number Publication date
IL134716A0 (en) 2001-04-30
UA56257C2 (uk) 2003-05-15
EP0919236A1 (en) 1999-06-02
AU9128298A (en) 1999-04-12
US6028070A (en) 2000-02-22
CN1270520A (zh) 2000-10-18
WO1999015176A1 (en) 1999-04-01
EA200000349A1 (ru) 2000-10-30
TR200000755T2 (tr) 2000-09-21
CN1146412C (zh) 2004-04-21
HUP0003591A2 (hu) 2002-01-28
HUP0003591A3 (en) 2002-02-28
NZ502810A (en) 2002-03-01
PL339426A1 (en) 2000-12-18
JP2001517627A (ja) 2001-10-09
AU740109B2 (en) 2001-11-01
CA2304115A1 (en) 1999-04-01
NO20001458D0 (no) 2000-03-21
KR20010024218A (ko) 2001-03-26
EA002689B1 (ru) 2002-08-29
NO20001458L (no) 2000-03-21

Similar Documents

Publication Publication Date Title
BR9812357A (pt) Tratamento de distúbio oposicional desafiador
BR9812371A (pt) Tratamento de distúrbio de conduta
TR200200204T2 (tr) MEK inhibitörleri kullanılarak kronik ağrının tedavi edilmesi.
PT971713E (pt) Utilizacao de inibidores da colinesterase para tratamento de desordens da atencao
BR9805544A (pt) Uso de um composto.
RS50091B (sr) Upotreba retigabina u lečenju neuropatskog bola
BR9710994A (pt) Derivados anticonvulsivos úteis no tratamento de obesidade.
PT912176E (pt) Utilizacao de amidas do acido piridil-alcanoico piridil-alcenoico e/ou piridil-alcinico para o tratamento de tumores ou para imunossupressao
BR0312785A (pt) Tratamento de desordens relacionadas a tnf(alfa)
DE69432984D1 (de) Therapeutische substituierte guanidine
EA199900448A1 (ru) Производные 6-фенилпиридил-2-амина, полезные в качестве ингибиторов nos
MY129189A (en) Prostaglandin agonists and their use to treat bone disorders
BR9909110A (pt) Usos de esmilagenina e anzurogenina d, compoisção farmacêutica tendo propriedades intensificadoras da função cognitiva, processo para intensificar a função cognitiva, e, composição para uso do mesmo
CY2607B2 (en) Synergistic combination of pde inhibitors and adenylate cyclase agonists or guanylcyclyse agonists
EA200401471A1 (ru) Применение ингибиторов сетр и возможных ингибиторов hmg coa и/или антигипертензивных агентов
BR9701248A (pt) Novos pró-medicamentos para a terapia de tumores e distúrbios inflamatórios
DK0946166T3 (da) Anvendelse af matrixmetalloproteinaseinhibitorer til fremme af sårheling
DE60141636D1 (de) Phospholipidderivate von valproinsäure und ihre kombinationen
BR9907655A (pt) Derivados de ácido di-hidróxi-hexanóico
EA200000165A1 (ru) Разветвленные алкоксизамещенные-2-аминопиридины в качестве ингибиторов nos
BR9712141A (pt) Aplicação de 1-hifróxi-2-piridonas para tratamento de infecções cutâneas.
BR9908214A (pt) Tratamento para linfomas foliculares utilizando inibidores da via da linfotoxina (lt)
MY136367A (en) Treatment of cognitive failure
ATE225171T1 (de) Aminosäurederivate zur behandlung von schlaganfall
BR9808299A (pt) O uso de levobupivacaìna ou ropivacaìna para o tratamento da enxaqueca

Legal Events

Date Code Title Description
B09B Patent application refused [chapter 9.2 patent gazette]